NCT01845350

Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients

Safety and Feasibility of Autologous M2 Macrophage Transplantation in Treatment of Non-Acute Stroke Patients

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Siberian Branch of the Russian Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether M2 macrophages are safe and feasible in the treatment of non-acute stroke patients

Detailed description

Our primary hypothesis is that autologous M2 macrophage transplantation via intrathecal introduction is feasible and safe after non-acute stroke. Our secondary hypothesis is that autologous M2 macrophage transplantation is associated with improved neurological outcome after non-acute stroke

Conditions

• Ischemic Stroke
• Hemorrhagic Stroke

Interventions

Type	Name	Description
OTHER	M2 macrophage introduction	* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients * Intrathecal introduction of autologous M2 macrophages

Timeline

• Start date: 2012-10-01
• Primary completion: 2014-04-01
• Completion: 2015-10-01
• First posted: 2013-05-03
• Last updated: 2016-11-04

Locations

1 site across 1 country: Russia